Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In vitro maturation is a long-studied technique used to obtain mature oocytes outside the human body. However, this method can increase the risk of ovarian hyperstimulation syndrome (OHSS), particularly in patients with polycystic ovarian syndrome (PCOS). Culture media supplemented with platelet-rich plasma (PRP) has previously shown promise for improving oocyte maturation. This study examined the potential utility of allogeneic PRP supplementation to increase the maturation of germinal vesicle (GV)-stage oocytes collected from PCOS patients who underwent controlled ovarian stimulation. Supplementation with 5% PRP was found to support oocyte maturation under controlled ovarian stimulation. Further investigations are required to refine the use of PRP without controlled ovarian stimulation in clinical IVM protocols that may be beneficial for PCOS patients.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PRP plasma rich platelets | Experimental | An initial pilot experiment tested with PRP supplementation to address oocyte maturation |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PRP plasma rich platelets | Other | An initial pilot experiment tested three different concentrations of PRP supplementation (5%, 25%, and 50%) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Optimal PRP Concentration | A concentration of 5% PRP was optimal rather than concentrations of 25% and 50% (cells are clumping and also associated with morphological abnormalities, such as cytoplasmic vacuolization, irregular perivitelline space, and abnormal polar bodies) | After 24 hours of culture incubation |
| Measure | Description | Time Frame |
|---|---|---|
| Oocyte maturation rate | After optimation, this study used PRP with concentration 5% tu supplementing IVM culture media. The 5% PRP supplementation group showed a significantly higher rate of oocyte maturation compared to the control group (non-PRP group) | After 24 hours of culture incubation |
| Oocyte morphological quality and fertilization rate |
Not provided
Inclusion Criteria:
Exclusion Criteria:
- Oocytes obtained from patients with comorbid conditions, including cancer, congenital adrenal hyperplasia, Cushing's syndrome, premature ovarian failure (POF) or premature ovarian insufficiency, liver disorders, kidney disease, cardiovascular disease, diabetes mellitus (type 1 or type 2), and patients receiving steroid therapy
PCOS patients who underwent IVF treatment who met Rotterdam 2003 inclusion criteria
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dr. Sardjito General Hospital | Yogyakarta | Special Region of Yogyakarta | Indonesia |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| Result | Prasath EB. Time line in IVF laboratory. Fertility Science and Research. 2023; 10: 15-19. https://doi.org/10.4103/fsr.fsr_6_23 |
Not provided
Not provided
IPD will not be shared due to participant privacy and confidentiality considerations
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan: Sudy Protoocol-Statistical Analysis Revised | Jan 5, 2023 | Mar 30, 2026 | Prot_SAP_000.pdf |
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan: Sudy Protocol-Statistical Analysis Revised 2 | Jan 5, 2023 | Apr 1, 2026 | Prot_SAP_001.pdf |
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan: Study Protocol and Statistical Analysis (old version) | Jan 5, 2023 | Mar 23, 2026 | Prot_SAP_002.pdf |
Not provided
| ID | Term |
|---|---|
| D011085 | Polycystic Ovary Syndrome |
| ID | Term |
|---|---|
| D010048 | Ovarian Cysts |
| D003560 | Cysts |
| D009369 | Neoplasms |
| D010049 | Ovarian Diseases |
| D000291 |
Not provided
Not provided
Prospective cohort study using PRP-supplementation in culture media
Not provided
Not provided
Not provided
Not provided
The PRP 5% group had a higher average TOS than the control group (non-PRP) and the fertilization rate in the PRP 5% group was 80% descriptively |
| After 24 hours of culture incubation |
| Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D006058 | Gonadal Disorders |
| D004700 | Endocrine System Diseases |